Pharmacists must take time to understand why patients are not adherent to HIV pre-exposure prophylaxis (PrEP) and what barriers exist, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy, talks about the pharmacist's role in educating patients on HIV risk and promoting pre-exposure prophylaxis (PrEP) adherence.
Transcript
What is the pharmacist’s role in making PrEP therapies available to people at high risk of contracting HIV?
The biggest role that pharmacists can have is educating patients about their risk level. I think right now there's a big community-wide knowledge gap about what the risk factors are and who would benefit from PrEP, so as pharmacists, we can be patient facing, we can do a lot of education within the community. We're also seeing a lot of states are passing collaborative practice agreements and PrEP protocols for pharmacists to be able to prescribe PrEP and continue therapy for patients. So I think really expanding access where possible.
What is their role in promoting adherence?
Very similar. As pharmacists, we're able to see what prescriptions patients are filling, how often they're coming in to get their refills. So, [we're] really able to help keep patients on track with their medications, identifying any gaps. We can reach out and understand where the nonadherence comes from. I think that's a big concern. We learn that adherence is an issue, and a lot of times we'll just label the patient is either nonadherent or they're not taking their medicine. We need to take the time to understand why they're not taking their medications and what barriers there are. I think pharmacists are really instrumental in that role.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More